Horizon Therapeutics USA, Inc. Credit Rating

Resultados 1 - 50 de 64

Página de 2 Next

Filtrar por:

Fecha	Tipo de Reporte	Título	Fuente
27 Jul 2023	Announcement of Periodic Review	Moody's announces completion of a periodic review for a group of Pharmaceutical issuers	Moody's Investors Service
16 May 2023	Announcement	Moody's: Amgen's and Horizon Therapeutics' ratings unaffected by FTC recent filing to block the acquisition	Moody's Investors Service
13 Dec 2022	Credit Opinion	Horizon Therapeutics USA, Inc.: Update following ratings under review for upgrade	Moody's Investors Service
12 Dec 2022	Rating Action	Moody's places Horizon Therapeutics' ratings on review for upgrade for proposed acquisition by Amgen	Moody's Investors Service
04 Oct 2022	Announcement of Periodic Review	Moody's announces completion of a periodic review for a group of Pharmaceutical issuers	Moody's Investors Service
31 Mar 2022	LGD Assessment	Horizon Therapeutics plc	Moody's Investors Service
21 Mar 2022	Credit Opinion	Horizon Therapeutics USA, Inc.: Update following upgrade to Ba1	Moody's Investors Service
18 Mar 2022	Rating Action	Moody's upgrades Horizon Therapeutics to Ba1; stable outlook	Moody's Investors Service
10 Nov 2021	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Horizon Therapeutics USA, Inc.	Moody's Investors Service
10 Jun 2021	Credit Opinion	Horizon Therapeutics USA, Inc.: Tepezza growth to continue while Uplizna enhances the rare disease franchise	Moody's Investors Service
25 Feb 2021	Announcement	Moody's: Horizon's term loan upsizing modestly credit negative	Moody's Investors Service
25 Feb 2021	Issuer Comment	Horizon Therapeutics USA, Inc.: Upsized term loan modestly increases financial leverage; ratings unaffected	Moody's Investors Service
18 Feb 2021	Rating Action	Moody's assigns Ba1 rating to Horizon Therapeutics' sr. secured term loan	Moody's Investors Service
03 Feb 2021	Rating Action	Moody's affirms Horizon Therapeutics at Ba2; stable outlook	Moody's Investors Service
15 Dec 2020	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Horizon Therapeutics USA, Inc.	Moody's Investors Service
24 Jul 2020	LGD Assessment	Horizon Therapeutics plc	Moody's Investors Service
10 Jun 2020	Credit Opinion	Horizon Therapeutics USA, Inc.: Update to credit analysis following upgrade to Ba2	Moody's Investors Service
09 Jun 2020	Rating Action	Moody's upgrades Horizon Therapeutics to Ba2; stable outlook	Moody's Investors Service
05 Feb 2020	Credit Opinion	Horizon Therapeutics USA, Inc.: Update to credit analysis following change in outlook to positive from stable	Moody's Investors Service
04 Feb 2020	Rating Action	Moody's revises Horizon Therapeutics' outlook to positive; affirms Ba3 CFR	Moody's Investors Service
14 Jan 2020	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Horizon Therapeutics USA, Inc.	Moody's Investors Service
22 Jul 2019	Covenant Quality Assessment	Horizon Pharma USA, Inc.: Covenant Quality Post-Sale Snapshot: $600m 5.500% Senior Notes due 2027	Moody's Investors Service
19 Jul 2019	Credit Opinion	Horizon Pharma USA, Inc.: Update to credit analysis following senior note refinancing	Moody's Investors Service
18 Jul 2019	LGD Assessment	Horizon Therapeutics plc	Moody's Investors Service
10 Jul 2019	Covenant Quality Assessment	Horizon Pharma USA, Inc.: Loan Covenant Quality Snapshot	Moody's Investors Service
10 Jul 2019	Rating Action	Moody's assigns B1 to Horizon's new sr. unsecured notes	Moody's Investors Service
15 May 2019	Rating Action	Moody's assigns Ba1 rating to Horizon's senior secured term loan	Moody's Investors Service
11 Apr 2019	Covenant Quality Assessment	Horizon Pharma Inc.: Loan Covenant Quality Snapshot	Moody's Investors Service
21 Mar 2019	Credit Opinion	Horizon Pharma USA, Inc.: Update to credit analysis following upgrade to Ba3	Moody's Investors Service
20 Mar 2019	Rating Action	Moody's upgrades Horizon Pharma to Ba3; stable outlook	Moody's Investors Service
05 Mar 2019	Rating Action	Moody's reviews Horizon Pharma's ratings for upgrade	Moody's Investors Service
15 Feb 2019	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Horizon Pharma USA, Inc.	Moody's Investors Service
18 Dec 2018	Credit Opinion	Horizon Pharma USA, Inc.: Update following change in outlook to stable from negative	Moody's Investors Service
17 Dec 2018	Rating Action	Moody's affirms Horizon Pharma's B2 CFR; revises outlook to stable from negative	Moody's Investors Service
10 May 2018	Credit Opinion	Horizon Pharma, Inc.: Update to credit analysis	Moody's Investors Service
10 Apr 2018	Covenant Quality Assessment	Horizon Pharma, Inc.: Loan Covenant Quality Snapshot	Moody's Investors Service
10 May 2017	Credit Opinion	Horizon Pharma, Inc.: Update to Discussion of Key Rating Factors	Moody's Investors Service
09 May 2017	LGD Assessment	Horizon Pharma PLC	Moody's Investors Service
09 May 2017	Rating Action	Moody's affirms Horizon Pharma; revises outlook to negative	Moody's Investors Service
22 Mar 2017	Credit Opinion	Horizon Pharma, Inc.: Update to Discussion of Key Rating Factors	Moody's Investors Service
22 Mar 2017	Rating Action	Moody's affirms Horizon Pharma at B2, raises SGL rating to SGL-1; stable outlook	Moody's Investors Service
21 Oct 2016	LGD Assessment	Horizon Pharma PLC	Moody's Investors Service
16 Oct 2016	Announcement	Moody's Publishes Covenant Quality Assessment for Horizon Pharma, Inc. / Horizon Pharma USA, Inc.	Moody's Investors Service
14 Oct 2016	Covenant Quality Assessment	Horizon Pharma, Inc. / Horizon Pharma USA, Inc.: Covenant Quality Pre-Sale Snapshot: $300m _% Senior Notes due 2024	Moody's Investors Service
13 Oct 2016	Covenant Quality Assessment	Horizon Pharma Financing Inc. (to be merged with and into Horizon Pharma, Inc.): Covenant Quality Post-Sale Snapshot: $475m 6.625% Senior Notes due 2023	Moody's Investors Service
13 Oct 2016	Credit Opinion	Horizon Pharma, Inc.: Update to Discussion of Key Rating Factors Following Acquisition of Raptor	Moody's Investors Service
13 Oct 2016	Rating Action	Moody's affirms Horizon Pharma's B2 CFR; downgrades unsec. rating to B3	Moody's Investors Service
12 Sep 2016	Announcement	Moody's: Horizon's Raptor acquisition credit negative	Moody's Investors Service
12 Sep 2016	Issuer Comment	Horizon Pharma, Inc.: Raptor acquisition is credit negative	Moody's Investors Service
20 Apr 2016	Credit Opinion	Horizon Pharma, Inc.: Update to Discussion of Key Rating Factors	Moody's Investors Service

Resultados 1 - 50 de 64

Página de 2 Next

Estudios & Calificaciones

Productos & Soluciones

Noticias & Eventos

Usuarios Registrados

¿No se ha registrado?

Moody's Integrity Hotline

Via the Internet:

By telephone from the United States:

By telephone from outside the United States: